Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver

Cancer Gene Therapy

Volumn 19, Issue 11, 2012, Pages 779-787

  Obeng Adjei, N ^a   Choo, D K ^a   Saini, J ^a   Yan, J ^b   Pankhong, P ^a   Parikh, A ^a   Chu, J S ^a   Weiner, D B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Inovio Pharmaceuticals Inc   (United States)

Author keywords

consensus; DNA vaccine; HBcAg; HBV; hydrodynamic injection

Indexed keywords

DNA VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE; IONOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; FEMALE; GENETIC CODE; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNIZATION; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; T LYMPHOCYTE; TARGET CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENES, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATOCYTES; LIVER; MICE; MICE, INBRED BALB C; PLASMIDS; TRANSFECTION; VACCINATION; VACCINES, DNA;

HEPATITIS B VIRUS; MUS;

EID: 84867747539     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.61     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
3. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 2010; 40: 14-30.
4. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526.
5. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-125.
6. Michel ML, Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005; 34(Supplement 1): S108-S114.
7. Cao G-W. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009; 15: 5761-5769.
8. Lin C-L, Kao J-H. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26: 123-130.
9. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25: 97-106.
10. Yan J, Corbitt N, Pankhong P, Shin T, Khan A, Sardesai NY et al. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine 2011; 29: 7173-7181.
11. Lin Y-J, Huang L-R, Yang H-C, Tzeng H-T, Hsu P-N, Wu H-L et al. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc Natl Acad Sci 2010; 107: 9340-9345.
12. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145(10): 3442-3449.
13. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992; 89(1): 87-96.
14. Xing Y-P, Huang Z-H, Wang S-X, Cai J, Li J, Chou T-H et al. Novel DNA vaccine based on hepatitis B virus core gene induces specific immune responses in Balb/c mice. World J Gastroenterol 2005; 11(29): 4583-4586.
15. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008; 26(3): 440-448.
16. Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 2008; 3(6): e2517.
17. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D, Weiner DB. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 2008; 26(40): 5210-5215.
18. Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26(25): 3112-3120.
19. Shedlock DJ, Talbott KT, Cress C, Ferraro B, Tuyishme S, Mallilankaraman K et al. A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine 2011; 29: 6755-6762.
20. Choo DK, Murali-Krishna K, Anita R, Ahmed R. Homeostatic turnover of virus-specific memory CD8 T cells occurs stochastically and is independent of CD4 T cell help. J Immunol 2010; 185(6): 3436-3444.
21. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005; 175(1): 112-123.
22. Shedlock DJ, Talbott KT, Morrow MP, Ferraro B, Hokey DA, Muthumani K et al. Ki-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo. Cytometry Part A 2010; 77A(3): 275-284.
23. Barber DL, Wherry EJ, Ahmed R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 2003; 171(1): 27-31.
24. Durward MA, Harms J, Magnani DM, Eskra L, Splitter GA. Discordant brucella melitensis antigens yield cognate CD8\+ T cells in vivo. Infect Immun 2010; 78(1): 168-176.
25. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepato-cytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10(10): 1735-1737.
26. Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis 2005; 192(12): 2112-2116.
27. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci 2002; 99(21): 13825-13830.
28. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98(5): 1185-1194.
29. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH et al. CD8\+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77(1): 68-76.
30. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4(1): 25-36.
31. Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-{kappa}B. J Virol 2003; 77(7): 4033-4042.
32. Chang JJ, Wightman F, Bartholomeusz A, Ayres A, Kent SJ, Sasadeusz J et al. Reduced hepatitis B virus (HBV)-specific CD4\+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol 2005; 79(5): 3038-3051.
33. Reignat S, Webster GJM, Brown D, Ogg GS, King A, Seneviratne SL et al. Escaping high viral load exhaustion. J Exp Med 2002; 195(9): 1089-1101.
34. Chang JJL, Sharon R. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2006; 85: 1.
35. Pillet SP, Kobasa D, Meunier I, Gray M, Laddy D, Weiner DB et al. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine 2011; 29: 6793-6801.
36. Peng J-L, Zhao Y-G, Mai J-H, Pang W-K, Guo W, Chen G-M et al. Non-cytolytic antigen clearance in DNA-vaccinated mice with electroporation. Acta Pharmacol Sin 2007; 28(7): 1024-1030.
37. Kuhröber A, Wild J, Pudollek HP, Chisari FV, Reimann J. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb-and Kd-restricted epitopes. Int Immunol 1997; 9(8): 1203-1212.
38. Sällberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 1998; 9(12): 1719-1729.
39. Livingston BD, Crimi C, Fikes J, Chesnut RW, Sidney J, Sette A. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. Hum Immunol 1999; 60(11): 1013-1017.
40. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007; 81(16): 8468-8476.
41. Yin Y, Wu C, Song J, Wang J, Zhang E, Liu H et al. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PLoS ONE 2011; 6(7): e22524.